tradingkey.logo

electroCore, Inc.

ECOR
View Detailed Chart
4.600USD
+0.180+4.07%
Close 12/19, 16:00ETQuotes delayed by 15 min
35.12MMarket Cap
LossP/E TTM

electroCore, Inc.

4.600
+0.180+4.07%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.07%

5 Days

-3.16%

1 Month

+0.22%

6 Months

-10.33%

Year to Date

-71.62%

1 Year

-69.88%

View Detailed Chart

TradingKey Stock Score of electroCore, Inc.

Currency: USD Updated: 2025-12-19

Key Insights

electroCore, Inc.'s fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 107/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.08.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

electroCore, Inc.'s Score

Industry at a Glance

Industry Ranking
107 / 208
Overall Ranking
245 / 4582
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
21.080
Target Price
+330.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

electroCore, Inc. Highlights

StrengthsRisks
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 193.09% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.18M.
Fairly Valued
The company’s latest PE is -2.70, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 233.47K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.69.

electroCore, Inc. News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

electroCore, Inc. Info

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Ticker SymbolECOR
CompanyelectroCore, Inc.
CEOGoldberger (Daniel S)
Websitehttps://www.electrocore.com/

FAQs

What is the current price of electroCore, Inc. (ECOR)?

The current price of electroCore, Inc. (ECOR) is 4.600.

What is the symbol of electroCore, Inc.?

The ticker symbol of electroCore, Inc. is ECOR.

What is the 52-week high of electroCore, Inc.?

The 52-week high of electroCore, Inc. is 19.490.

What is the 52-week low of electroCore, Inc.?

The 52-week low of electroCore, Inc. is 4.160.

What is the market capitalization of electroCore, Inc.?

The market capitalization of electroCore, Inc. is 35.12M.

What is the net income of electroCore, Inc.?

The net income of electroCore, Inc. is -11.89M.

Is electroCore, Inc. (ECOR) currently rated as Buy, Hold, or Sell?

According to analysts, electroCore, Inc. (ECOR) has an overall rating of Buy, with a price target of 21.080.

What is the Earnings Per Share (EPS TTM) of electroCore, Inc. (ECOR)?

The Earnings Per Share (EPS TTM) of electroCore, Inc. (ECOR) is -1.704.
KeyAI